Clinical trial · Observational
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy
Comparison of the Occurrence of HBV Reactivation According to the Duration of Preemptive Antiviral Therapy in Chronic Hepatitis B Virus Carriers Receiving Cancer Chemotherapy for Hematologic Diseases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Previous studies dealt with patients who maintained antiviral drugs for 2 \~ 6 months after final chemotherapy and they revealed that many of the patients who stopped preemptive antiviral drug within 6 months experienced viral reactivation. Based on the study results, guidelines recommend that preemptive antiviral therapy should be maintained for at least 6 months. Nevertheless, many clinicians apply the preemptive antiviral drugs for 1\~2 years or longer after final chemotherapy without definite evidences, and this practice increases the medical expenditure a lot. Therefore, the investigators are going to find out the proper and safe duration of preemptive antiviral therapy which can be a good reference in the future practice.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Hepatitis B | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Cumulative incidence rate of hepatitis B viral reactivation
- timeFrame
- within one year after cessation of the antiviral drug
Secondary outcomes (1)
- measure
- Severity of reactivation of hepatitis B
- timeFrame
- within one year after cessation of anviral drugs
- description
- Severity according to ALT (IU/L) level Mild : up to 5 times from upper normal limit Moderate : 5- 10 times from upper normal limit Severe : ALT \> 300 IU/L or ≥ 10 times
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years old or older * ECOG performance status 0, 1, 2 * Hodgkin's or Non-Hodgkins lymphomas according to the WHO 2008 classification * Patients who received standard cytotoxic chemotherapies * Patients who finished chemotherapy (duration not exceeded 6 months) or who will finish the planned chemotherapy * Patients who achieved at least partial response and do not need further chemotherapy * HBsAg (+) patients who received preemptive antiviral therapies Exclusion Criteria: * Anti-HCV Ab(+), HIV(+), or autoimmune hepatitis * Complications due to uncompensated liver cirrhosis * Child pugh score : 10 points or more * Hepatocellular carcinoma * Patients who finish the lymphoma treatments with only radiotherapy
References
Publications (0)
Data not yet available